These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19491620)

  • 1. Benefits of the RAS blockade: clinical evidence before the ONTARGET study.
    Perret-Guillaume C; Joly L; Jankowski P; Benetos A
    J Hypertens Suppl; 2009 Jun; 27(2):S3-7. PubMed ID: 19491620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M
    Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V
    J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
    Sandmann S; Unger T
    Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual blockade versus single blockade of the renin-angiotensin system in the light of ONTARGET.
    Sudano I; Noll G
    J Hypertens Suppl; 2009 Jun; 27(2):S11-4. PubMed ID: 19491615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin-Aldosterone system inhibition in prevention of diabetes mellitus.
    Bălută M; Vintilă V; Vintilă M
    Rom J Intern Med; 2004; 42(2):277-88. PubMed ID: 15529618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies on the blockade of the renin-angiotensin-aldosterone-system.
    Hennig L
    Clin Nephrol; 2003 Jul; 60 Suppl 1():S53-8. PubMed ID: 12940534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G; Ostergren J; Struijker-Boudier H
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle.
    Henriksen EJ; Prasannarong M
    Mol Cell Endocrinol; 2013 Sep; 378(1-2):15-22. PubMed ID: 22564510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.